# A Study of GQ1010 in Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06464055/  
OnCo record `nct06464055` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Dose Escalation in advanced solid tumours, run by GeneQuantum Healthcare (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of GQ1010 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06464055 by GeneQuantum Healthcare (Suzhou) Co., Ltd., with 260 participants planned, started 2024-05-23 and due to reach its primary completion in 2028-05-23. Interventions recorded: Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3 and phase II.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06464055
- Phase: 1/2
- Setting: A Phase I/II, Multicenter, Open-Label, Dose-Escalation and Extension Study of GQ1010(an Anti-Trop2 ADC) in Subjects With Advanced Solid Tumors
- Sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd.
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT06464055: https://clinicaltrials.gov/study/NCT06464055

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06464055.json